Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Areesha Moiz, Jeremy Y. Levett, Kristian B. Filion, et al.
The American Journal of Cardiology (2024) Vol. 222, pp. 121-130
Open Access | Times Cited: 16

Showing 16 citing articles:

How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Ralf Weiskirchen, Amedeo Lonardo
British Journal of Pharmacology (2025)
Open Access | Times Cited: 3
IUPHAR review: Drug Repurposing in Schizophrenia – An Updated Review of Clinical Trials
Jihan K. Zaki, Jakub Tomasik, Sabine Bahn
Pharmacological Research (2025), pp. 107633-107633
Open Access
Once‐Weekly Semaglutide Versus Once‐Daily Liraglutide for Weight Loss in Adults: A Meta‐Analysis of Randomized Controlled Trials
Tallal Mushtaq Hashmi, Mushood Ahmed, Ali Haider, et al.
Clinical and Translational Science (2025) Vol. 18, Iss. 2
Open Access
The Role of GLP-1 Agonists in Mitigating Lorlatinib-induced Metabolic Syndrome: Two Case Studies
Erica Pietroluongo, Silvana Pannain, Marina Chiara Garassino, et al.
Clinical Lung Cancer (2025)
Closed Access
Treating class 2–3 obesity with glucagon‐like peptide‐1 agonists: A 2‐year real‐world cohort study
Mona Abdel‐Bary, Andrea Bródy, Jochen Schmitt, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Investigating the Impact of GLP-1 Receptor Agonist-Induced Fat Loss on Collagen Synthesis and Skin Elasticity
Alejandra Sataray-Rodriguez, Donna Pham, Ceilia Severini, et al.
Journal of Biomedical Science and Engineering (2025) Vol. 18, Iss. 03, pp. 45-59
Open Access
Effects of Semaglutide on Glycemic Control and Body Weight in Patients With Type 2 Diabetes: A Retrospective Cohort Study in a Primary Care Setting
Mahmoud A. Alzahrani, Lama Rammal, Razaz Felemban, et al.
Cureus (2025)
Open Access
GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review
Candace Jarade, Tetiana Zolotarova, Areesha Moiz, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102789-102789
Open Access | Times Cited: 3
Semaglutide “Ozempic” Face and Implications in Cosmetic Dermatology
Karen Montecinos, Barbara Kania, David J. Goldberg
Dermatological Reviews (2024) Vol. 5, Iss. 5
Closed Access | Times Cited: 1
SELECT: Glucagon-like peptide-1 receptor agonist in obese patients with cardiovascular disease in the absence of diabetes
Susy Kotit, Marina Sous
Global Cardiology Science and Practice (2024) Vol. 2024, Iss. 4
Open Access
In vivo Antibody Painting for Next Generation Weight Loss Drugs
Katsushi Kitahara, Aurélie Rondon, Edward Miller, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Exposure to GLP‐1 receptor agonists in early pregnancy did not increase the risk of congenital malformations
Ilari Kuitunen
Acta Paediatrica (2024) Vol. 113, Iss. 12, pp. 2682-2683
Open Access
Supporting the treatment of obesity
David Phizackerley
Drug and Therapeutics Bulletin (2024), pp. dtb-000053
Closed Access
Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes
Noelle N. Gronroos, Caroline Swift, Monica Frazer, et al.
Journal of health economics and outcomes research (2024), pp. 118-124
Open Access
Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes
Noelle N. Gronroos, Caroline Swift, Monica Frazer, et al.
Journal of health economics and outcomes research (2024) Vol. 11, Iss. 2
Open Access
Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
Miodrag Janić, Sabina Škrgat, Matevž Harlander, et al.
Medicina (2024) Vol. 60, Iss. 12, pp. 2030-2030
Open Access
Rational approaches to the treatment of patients with overweight and obesity: a cardiologist’s view
S. V. Miklishanskaya, Н. А. Мазур
Rational Pharmacotherapy in Cardiology (2024) Vol. 20, Iss. 6, pp. 652-659
Open Access
Page 1

Scroll to top